Journal
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
Volume 21, Issue 7, Pages 1328-1333Publisher
BMJ PUBLISHING GROUP
DOI: 10.1097/IGC.0b013e31821d6021
Keywords
Aromatase inhibitors; Gynecological neoplasms; Ovarian neoplasms; Endometrial neoplasms; Hormonal therapy
Categories
Funding
- NHMRC [570893]
- Cancer Australia and the Cancer Institute NSW
- Australia New Zealand Gynaecological Oncology Group
- Cancer Research UK [12846] Funding Source: researchfish
Ask authors/readers for more resources
Many gynecological cancers, including epithelial and stromal ovarian cancers; endometrial carcinomas; and some gynecological sarcomas, in particular endometrial stromal sarcomas, express estrogen and/ or progesterone receptors. Hormonal therapy, typically progestogens or tamoxifen, is commonly prescribed to patients with potentially hormone-sensitive recurrent or metastatic gynecological cancers with very variable response rates and clinical benefit reported. Aromatase inhibitors are now widely used to treat postmenopausal women with hormone receptor-positive breast cancers as they have greater activity than tamoxifen and are generally better tolerated. The role of aromatase inhibitors in gynecological cancers is uncertain and has not been well studied, although they do appear to be active. The current evidence to support the use of hormonal therapies including aromatase inhibitors in gynecological cancers is reviewed, and the gaps in our knowledge highlighted.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available